Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40Z30 | ISIN: US29970R3030 | Ticker-Symbol:
NASDAQ
05.06.25 | 21:27
2,630 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EVAXION A/S ADR Chart 1 Jahr
5-Tage-Chart
EVAXION A/S ADR 5-Tage-Chart

Aktuelle News zur EVAXION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEvaxion secures Gates Foundation grant for polio vaccine2
DiEvaxion A/S - 6-K, Report of foreign issuer2
DiEvaxion Biotech: Evaxion receives grant funding to design new polio vaccine247Evaxion awarded a grant from the Gates FoundationGrant funds research aimed at ultimately eradicating polio, a highly infectious viral diseaseEvaxion will apply its leading AI-Immunology platform to...
► Artikel lesen
28.05.H.C. Wainwright maintains Buy on Evaxion Biotech with $14 PT2
28.05.Evaxion targets at least two new business development deals in 2025 while maintaining cash runway to mid-20263
27.05.Evaxion reports progress in cancer vaccine trial, extends cash runway2
27.05.Evaxion Biotech: Evaxion announces business update and first quarter 2025 financial results297COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/SAbout Evaxion Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction...
► Artikel lesen
27.05.Evaxion meldet Fortschritte bei Krebsimpfstoff-Studie und verlängert Finanzierung11
EVAXION Aktie jetzt für 0€ handeln
27.05.Evaxion Biotech ADS GAAP EPS of -$0.012
26.05.A Look at Evaxion Biotech's Upcoming Earnings Report1
23.05.Evaxion Biotech: Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025283COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/Sto receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.To join the webcast...
► Artikel lesen
22.05.Evaxion auf der Sidoti-Konferenz: KI-gestützte Arzneimittelentwicklungsstrategie3
22.05.Evaxion A/S - 6-K, Report of foreign issuer2
22.05.Evaxion Biotech: Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01305Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data packageWill provide insights into...
► Artikel lesen
05.05.Evaxion Biotech A/S - 6-K, Report of foreign issuer1
28.04.Evaxion Reports Positive Data For Vaccine Candidate EVX-012
28.04.Evaxion's EVX-01 vaccine shows promising immune response in trial2
28.04.Evaxion Biotech A/S - 6-K, Report of foreign issuer10
28.04.Evaxion Biotech: 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting26880% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the precision...
► Artikel lesen
10.04.Evaxion Biotech: Evaxion to present at World Vaccine Congress253Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/SAbout EVAXION Evaxion Biotech A/S is a pioneering TechBio company based upon...
► Artikel lesen
Weiter >>
78 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1